Navidea Biopharmaceuticals (NAVB)
(Delayed Data from OTC)
$0.00 USD
0.00 (0.00%)
Updated Sep 20, 2024 12:29 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Navidea Biopharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | NA | 0 | 1 | 1 | 1 |
Cost Of Goods | NA | 0 | 0 | 0 | 0 |
Gross Profit | NA | 0 | 1 | 1 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 14 | 13 | 12 | 12 |
Income After Depreciation & Amortization | 0 | -14 | -12 | -11 | -11 |
Non-Operating Income | NA | 0 | 0 | 0 | 0 |
Interest Expense | NA | 1 | 0 | 0 | 0 |
Pretax Income | NA | -15 | -12 | -11 | -11 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -15 | -12 | -11 | -11 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -15 | -12 | -11 | -11 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -14 | -12 | -11 | -11 |
Depreciation & Amortization (Cash Flow) | NA | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | 0 | -14 | -12 | -11 | -11 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | 30.90 | 29.34 | 23.90 | 14.39 |
Diluted EPS Before Non-Recurring Items | NA | -0.56 | -0.40 | -0.48 | -0.76 |
Diluted Net EPS (GAAP) | NA | -0.56 | -0.40 | -0.48 | -0.76 |
Fiscal Year end for Navidea Biopharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | 0.00 | 0.00 |
Cost Of Goods | NA | NA | NA | 0.00 | 0.00 |
Gross Profit | NA | NA | NA | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 2.13 | 2.43 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | -2.13 | -2.43 |
Non-Operating Income | NA | NA | NA | -0.02 | 1.03 |
Interest Expense | NA | NA | NA | 0.10 | 0.00 |
Pretax Income | NA | NA | NA | -2.26 | -1.39 |
Income Taxes | NA | NA | NA | 0.00 | 0.00 |
Minority Interest | NA | NA | NA | 0.00 | 0.00 |
Investment Gains/Losses | NA | NA | NA | 0.00 | 0.00 |
Other Income/Charges | NA | NA | NA | 0.00 | 0.00 |
Income From Cont. Operations | NA | NA | NA | -2.26 | -1.39 |
Extras & Discontinued Operations | NA | NA | NA | 0.00 | 7.43 |
Net Income (GAAP) | NA | NA | NA | -2.26 | 6.03 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | 99.36 | 48.24 |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | -0.02 | -0.03 |
Diluted Net EPS (GAAP) | NA | NA | NA | -0.02 | 0.12 |